Glofitamab trial reports 73.3% complete response rate

ClinicalTrials.gov posted results on 2026-08-18 for a phase 2 study evaluating glofitamab with rituximab plus CHOP in untreated diffuse large B-cell lymphoma. Among the posted measurements, the end-of-treatment complete response rate was 73.3% in participants receiving glofitamab plus R-CHOP immunochemotherapy.

Background

The study evaluated glofitamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, a regimen identified in the record as R-CHOP. Its stated focus was the safety, efficacy, and pharmacokinetics of this combination as first-line treatment for individuals with circulating tumor DNA high-risk diffuse large B-cell lymphoma. The record lists lymphoma as the study condition and also includes tocilizumab among the interventions.

Trial design

This was an open-label, multicenter phase 2 study with enrollment of 46 participants. It evaluated glofitamab in combination with R-CHOP in individuals with untreated diffuse large B-cell lymphoma classified as circulating tumor DNA high risk. The study record listed an overall status of active, not recruiting. The supplied record did not list primary outcome measures.

Key results

The posted outcome was the end-of-treatment complete response rate for the glofitamab plus R-CHOP immunochemotherapy group. The reported result was 73.3%, expressed as the percentage of participants. The record identified a 95% confidence interval as the dispersion type, but no confidence-interval value was supplied. No p-values, additional key analyses, or adverse-event summary were provided in the supplied data.

What this means

The posted result gives a group-level complete response rate for glofitamab combined with R-CHOP in the study population. Because the supplied record does not include a comparator result, primary outcome measures, confidence-interval value, statistical analyses, or an adverse-event summary, the reported percentage alone does not establish comparative efficacy or safety.

Source

This article is based on results posted by ClinicalTrials.gov on 2026-08-18. The source document is the ClinicalTrials.gov study record for NCT04980222, available at clinicaltrials.gov.